Capital into your deals

Crossover & Growth Co-Investors

The crossover funds and growth investors that lead late-stage rounds and price pre-IPO paper — the capital your winners graduate to, and the co-investors that take companies from Series C to the public markets.

13 sources

Tiger Global

Notable

Firm

The crossover fund that redefined late-stage velocity.

Growth-stage and pre-IPO technology companies globallyView

Altimeter Capital

Firm

Concentrated crossover investor behind the Snowflake trade.

Growth-stage and pre-IPO software and internet companiesView

Baillie Gifford

Firm

Edinburgh partnership holding private growth for a decade-plus.

Late-stage growth companies with long-duration potentialView

Coatue

Firm

Tech-focused crossover investing from seed to public markets.

Growth-stage and pre-IPO technology companiesView

D1 Capital Partners

Firm

Public-private fund with a heavyweight private book.

Late-stage private companies and public equitiesView

Dragoneer Investment Group

Firm

Low-profile growth investor with a pre-IPO hit list.

Late-stage private and public growth companiesView

Durable Capital Partners

Firm

Henry Ellenbogen's long-duration growth crossover fund.

Late-stage private companies and small/mid-cap public growthView

Fidelity Investments

Firm

Trillions in mutual-fund capital reaching into private rounds.

Pre-IPO companies at mutual-fund scaleView

General Atlantic

Firm

The original growth-equity firm, at global scale.

Growth-stage companies raising $50M+ roundsView

Insight Partners

Firm

Software-only growth investor with an operating army.

High-growth software companies, Series A through pre-IPOView

SoftBank Vision Fund

Firm

The largest tech fund ever raised — and a market force.

Late-stage companies raising $100M+ roundsView

T. Rowe Price

Firm

Mutual-fund giant pricing late-stage private rounds.

Pre-IPO companies suitable for mutual-fund portfoliosView

Wellington Management

Firm

Institutional crossover manager, dominant in biotech rounds.

Late-stage growth and biotech companies approaching IPOView

Back to all funding categories